ライフサイエンスコーパス: hepatorenal

1 l cardiac defects, abnormal left-right axis, hepatorenal and pancreatic cysts, and embryonic lethalit

2 PAS is more effective than OCT in reducing hepatorenal cystogenesis in rodent models; therefore, it

3 h of cultured cysts in vitro, and inhibiting hepatorenal cystogenesis in vivo in PCK rats and Pkd2(WS

4 with autosomal dominant PKD (ADPKD); and (2) hepatorenal cystogenesis in vivo in PCK rats and Pkd2(WS

5 denosine monophosphate (cAMP) levels trigger hepatorenal cystogenesis.

6 e effect on aflatoxin B(1) (AFB(1))-mediated hepatorenal derangements in rats.

7 l diagnosis in young adults with fibrocystic hepatorenal disease.

8 kidney disease (ARPKD) is a severe pediatric hepatorenal disorder with pronounced phenotypic variabil

9 he prevalence and prognostic implications of hepatorenal dysfunction are unknown in this population.

10 Hepatorenal dysfunction is a predictor of mortality in E

11 Hepatorenal dysfunction is a risk factor for mortality i

12 al class, comorbidities, cardiac procedures, hepatorenal dysfunction, and ventricular/valvular dysfun

13 risk factors and prognostic implications of hepatorenal dysfunction, as measured primarily by the us

14 factors for death/transplant were older age, hepatorenal dysfunction, heart failure, and higher Fonta

15 The radiotracer showed a hepatorenal excretion pathway for clearance in an animal

16 es and hepatic hydrothorax, and treatment of hepatorenal failure and hepatopulmonary syndrome.

17 Fatal hepatorenal failure may occur after the use of hydrazine

18 te lethality associated with signs of severe hepatorenal failure when mice are fed with a diet that e

19 onephritis, and 1 with acetaminophen-induced hepatorenal failure).

20 olycystic kidney disease (ARPKD) is a severe hepatorenal fibrocystic disorder.

21 a mean age of 21.4 (+/-3.3) years describing hepatorenal findings.

22 entify patients at risk for deterioration in hepatorenal function and mortality.

23 tative backscatter parameters, including the hepatorenal index and backscatter coefficient, are being

24 Sonographic hepatorenal index was a determinant of subclinical ather

25 ters representing brightness (echointensity, hepatorenal index) and variance (heterogeneity, anisotro

26 r spectral imaging, attenuation coefficient, hepatorenal index, speed of sound, and backscatter-based

27 y liver disease, assessed by the sonographic hepatorenal index, was more prevalent in psoriasis than

28 ts have shown beneficial effects in managing hepatorenal injuries.

29 Hepatorenal involvement and preceding complications in o

30 hosphatemia reflects a derangement of normal hepatorenal messaging and is the result of a disruption

31 her lipid indexes or markers associated with hepatorenal or cardiovascular function.

32 In conclusion, Pkd2ws25/- mice exhibit hepatorenal pathology resembling human autosomal dominan

33 ogy in the orpk mutant mouse that displays a hepatorenal pathology that is similar to that seen in hu

34 Our results provide further support for hepatorenal reciprocity and may explain at least in part

35 ther observations have led to the concept of hepatorenal reciprocity.

36 on, renal blood flow declines because of the hepatorenal reflex, and is then maintained by the vasoac

37 Patients with sepsis (1.24 [1.23-1.25]), hepatorenal syndrome (1.22 [1.21-1.22]), and peritonitis

38 A higher proportion of patients on NSBBs had hepatorenal syndrome (24% vs 11% in those not taking NSB

39 a (68.6 %), acute tubular necrosis (25.7 %), hepatorenal syndrome (5.7 %), respectively.

40 (HE; 37.8%), variceal bleeding (VB; 17.5%), hepatorenal syndrome (6.3%), and spontaneous bacterial p

41 re effective at treating acute kidney injury-hepatorenal syndrome (AKI-HRS), liver transplantation (L

42 Secondary outcomes included hepatorenal syndrome (HR, 0.47 [95% CI, 0.40-0.56]), spo

43 re sepsis (27% versus 9%, P = 0.003), type-1 hepatorenal syndrome (HRS) (16% versus 3%, P = 0.002), a

44 with acute tubular necrosis (ATN) (n = 10), hepatorenal syndrome (HRS) (n = 18), and prerenal azotem

45 plications [hepatic encephalopathy, ascites, hepatorenal syndrome (HRS) and esophageal variceal hemor

46 Hepatorenal syndrome (HRS) carries a high short-term mor

47 Type-1 hepatorenal syndrome (HRS) is a common complication of b

48 Hepatorenal syndrome (HRS) is a form of kidney dysfuncti

49 Hepatorenal syndrome (HRS) is a rare and highly morbid f

50 Hepatorenal syndrome (HRS) is a serious complication of

51 Hepatorenal syndrome (HRS) is associated with high rates

52 nd albumin (triple therapy) is used to treat hepatorenal syndrome (HRS) often as a bridge to liver tr

53 Hepatorenal syndrome (HRS) type 1 is a progressive funct

54 Fourteen patients with LVDD developed hepatorenal syndrome (HRS) type 1 on follow-up.

55 e prerenal AKI), acute tubular necrosis, and hepatorenal syndrome (HRS), a functional type of prerena

56 The hepatorenal syndrome (HRS), a progressive but potentiall

57 Hepatorenal syndrome (HRS), a serious complication of ci

58 edict development of renal dysfunction (RD), hepatorenal syndrome (HRS), ACLF, and mortality.

59 s including hepatic encephalopathy, ascites, hepatorenal syndrome (HRS), and esophageal variceal hemo

60 plications [hepatic encephalopathy, ascites, hepatorenal syndrome (HRS), and esophageal variceal hemo

61 holipid syndrome (APLS), ESLD complicated by hepatorenal syndrome (HRS), and severe CAD who successfu

62 In patients with cirrhosis and hepatorenal syndrome (HRS), terlipressin has been used e

63 nally may be done for the renal diagnosis of hepatorenal syndrome (HRS).

64 mia (PRA), acute tubular necrosis (ATN), and hepatorenal syndrome (HRS).

65 oconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world

66 ctors and albumin is used in the reversal of hepatorenal syndrome (HRS-AKI), the most lethal complica

67 dney injury (AKI) in cirrhosis, particularly hepatorenal syndrome (HRS-AKI).

68 231 (62%) had pre-renal AKI; 61 (16.4%) had hepatorenal syndrome (HRS-AKI); 25 (6.7%) had HRS-AKD; 3

69 Type 2 hepatorenal syndrome (HRS2) is a functional renal impair

70 ions, spontaneous bacterial peritonitis, and hepatorenal syndrome (RR = 0.42, 95% CI 0.26-0.69, NNT =

71 2 situations within AKI (ie, with or without hepatorenal syndrome [HRS]), only HRS-AKI remained assoc

72 ncephalopathy, variceal hemorrhage [VH], and hepatorenal syndrome [HRS]).

73 oup (due to gastrointestinal haemorrhage and hepatorenal syndrome [n=1 each] and hepatic encephalopat

74 reversal of hepatorenal syndrome, relapse of hepatorenal syndrome after initial reversal, and adverse

75 ised, time of hospitalization, and risks for hepatorenal syndrome and acute kidney injury.

76 with secondary end points of development of hepatorenal syndrome and response to therapy based on th

77 re two forms of hepatorenal syndrome: type 1 hepatorenal syndrome and type 2 hepatorenal syndrome.

78 objective criteria of severity and recoding hepatorenal syndrome as a particular form of renal dysfu

79 Hepatorenal syndrome as the sole primary etiology of kid

80 t in native kidney function follows SLK, and hepatorenal syndrome as the sole primary etiology of kid

81 The cumulative incidence of hepatorenal syndrome at 6 months was not significantly d

82 Otherwise, hepatorenal syndrome carries a high mortality.

83 Recommended treatment for type 1 hepatorenal syndrome consists of albumin and vasoconstri

84 n methods for the treatment or prevention of hepatorenal syndrome except to maintain adequate hemodyn

85 erlipressin improved the rate of reversal of hepatorenal syndrome from 39% to 18%.

86 adrenaline-treated patients with reversal of hepatorenal syndrome had recurrence on discontinuation o

87 The development of hepatorenal syndrome in liver cirrhosis leads to an incr

88 ntaneous bacterial peritonitis is 11% and of hepatorenal syndrome is 8%; the latter is associated wit

89 Hepatorenal syndrome is a significant cause of acute kid

90 ients with acute liver failure (ALF) in whom hepatorenal syndrome is common.

91 avenous albumin therapy for the treatment of hepatorenal syndrome is ongoing with a growing body of r

92 Hepatorenal syndrome may improve by increasing renal blo

93 rgoing large-volume paracentesis or who have hepatorenal syndrome or spontaneous bacterial peritoniti

94 The hepatorenal syndrome represents the result of extreme va

95 The hepatorenal syndrome represents the result of extreme va

96 Hyponatremia and the hepatorenal syndrome result from water retention and ren

97 A meta-analysis was performed of hepatorenal syndrome reversal and survival in relation t

98 The pooled percentage of patients achieving hepatorenal syndrome reversal was 49.5% (95% confidence

99 significant increase of similar magnitude in hepatorenal syndrome reversal was also observed (odds ra

100 Neither survival nor hepatorenal syndrome reversal was significantly affected

101 CLKT patients with hepatorenal syndrome showed significantly higher patient

102 ars) with decompensated cirrhosis and type 1 hepatorenal syndrome that compared the efficacy of activ

103 Clinical studies of type 1 hepatorenal syndrome treatment with albumin and vasocons

104 Hepatorenal syndrome type 1 (HRS-1) in patients with cir

105 Hepatorenal syndrome type 1 (HRS-1) is a severe form of

106 Hepatorenal syndrome type 1 (HRS-1), which is a specific

107 o further decompensation (variceal bleeding, hepatorenal syndrome) and improves survival.

108 iceal hemorrhage, hepatic encephalopathy, or hepatorenal syndrome), liver transplant, and liver-relat

109 included other specific liver diagnoses (eg, hepatorenal syndrome), viral hepatitis, and hepatobiliar

110 nd reversible causes of renal failure (i.e., hepatorenal syndrome), whereas combined liver and kidney

111 Extreme renal vasoconstriction characterizes hepatorenal syndrome, a functional and potentially rever

112 y, alcohol-related liver disease can lead to hepatorenal syndrome, a severe type of kidney dysfunctio

113 t study using this shunt in the treatment of hepatorenal syndrome, a trial of antibiotic prophylaxis

114 No patient developed hepatorenal syndrome, and 1-year survival of 67% was bet

115 group (due to gastrointestinal haemorrhage, hepatorenal syndrome, and cerebrovascular accident [n=1

116 ores and prevents the development of sepsis, hepatorenal syndrome, and hepatic encephalopathy.

117 to high rates of acute kidney injury (AKI), hepatorenal syndrome, and mortality.

118 atment (one had acute kidney injury, one had hepatorenal syndrome, and one had renal failure).

119 0 days; incidence of infection, incidence of hepatorenal syndrome, and proportion of participants wit

120 ch as variceal bleeding, encephalopathy, and hepatorenal syndrome, and sociodemographic factors, such

121 sin is useful in patients with cirrhosis and hepatorenal syndrome, but there are no data of its use i

122 tudied to improve outcomes for patients with hepatorenal syndrome, but trials have reported variable

123 rrhotic patients with RF, in particular with hepatorenal syndrome, CLKT is preferable to LTA because

124 sociated with time-dependent change in eGFR, hepatorenal syndrome, dialysis requirement, hepatitis C,

125 gth of stay was associated with eGFR at OLT, hepatorenal syndrome, dialysis requirement, model for en

126 h as restless leg syndrome, sudden deafness, hepatorenal syndrome, erectile dysfunction, and so on.

127 In patients with hepatorenal syndrome, hemodialysis can be used as a brid

128 The percentages of patients who developed hepatorenal syndrome, hepatic encephalopathy, or sepsis

129 rmed in case of different conditions such as hepatorenal syndrome, hepatichydrothorax, portal vein th

130 cterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, hepatocellular carcinoma, hypoglyc

131 Hepatorenal syndrome, hepatocellular carcinoma, variceal

132 disposes the patient to variceal hemorrhage, hepatorenal syndrome, hepatopulmonary syndrome, and unco

133 evels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for

134 Hepatorenal syndrome, HRS, is a diagnosis of exclusion.

135 alopathy, ascites, hepatocellular carcinoma, hepatorenal syndrome, or bleeding caused by portal hyper

136 ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, or fulminant hepatic failure.

137 k of hospital death in patients with sepsis, hepatorenal syndrome, or peritonitis warrants further in

138 of hepatic encephalopathy, ascites, varices, hepatorenal syndrome, or spontaneous bacterial peritonit

139 er cancer, receipt of liver transplantation, hepatorenal syndrome, prolonged length of stay, and hosp

140 Secondary outcomes were reversal of hepatorenal syndrome, relapse of hepatorenal syndrome af

141 sode and secondary prophylaxis), ascites and hepatorenal syndrome, spontaneous bacterial peritonitis

142 cations (hyponatremia, hepatic hydrothorax), hepatorenal syndrome, spontaneous bacterial peritonitis,

143 ), portal hypertensive gastropathy, ascites, hepatorenal syndrome, spontaneous bacterial peritonitis,

144 peritonitis, in acute kidney injury, and in hepatorenal syndrome, the amount and schedule of albumin

145 ect a significant difference in incidence of hepatorenal syndrome, which was less frequent in the gro

146 de (OR 26.25, 95% CI 3.07-224.21) to reverse hepatorenal syndrome, with low-quality evidence supporti

147 Terlipressin reverses hepatorenal syndrome-acute kidney injury (HRS-AKI) by in

148 Treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI), with

149 to terlipressin and albumin in patients with hepatorenal syndrome-AKI (HRS-AKI), and (3) predicting i

150 ewer patients receiving colchicine developed hepatorenal syndrome.

151 serum creatinine and are more likely to have hepatorenal syndrome.

152 , ascites, encephalopathy, coagulopathy, and hepatorenal syndrome.

153 a, and its associated complications, such as hepatorenal syndrome.

154 diuretics for ascites, and terlipressin for hepatorenal syndrome.

155 acute kidney injury are discussed, including hepatorenal syndrome.

156 by the presence of hepatic encephalopathy or hepatorenal syndrome.

157 ctiveness and safety in patients with type 1 hepatorenal syndrome.

158 rolled trials done in 739 adults with type 1 hepatorenal syndrome.

159 ompared with placebo in patients with type 1 hepatorenal syndrome.

160 f different management strategies for type 1 hepatorenal syndrome.

161 plus octreotide with albumin for reversal of hepatorenal syndrome.

162 ompared with placebo in patients with type 1 hepatorenal syndrome.

163 , bacterial infection, and/or development of hepatorenal syndrome.

164 albumin and survival in patients with type 1 hepatorenal syndrome.

165 is useful in the management of patients with hepatorenal syndrome.

166 ut also heart failure in the pathogenesis of hepatorenal syndrome.

167 rome: type 1 hepatorenal syndrome and type 2 hepatorenal syndrome.

168 o the prevention and effective treatment for hepatorenal syndrome.

169 There are two forms of hepatorenal syndrome: type 1 hepatorenal syndrome and ty

170 Search terms included: hepatorenal syndrome; albumin; vasoconstrictor; terlipre

171 s of IAH may also be seen in cardiorenal and hepatorenal syndromes.

172 In vivo experiments did not show acute hepatorenal toxicity.

173 and progressive liver dysfunction, underwent hepatorenal transplantation.

174 including succinylacetone (SA), a marker for hepatorenal tyrosinemia.